Rezdiffra (Resmetirom) for NASH F2-F3: Off-Label Use and Monitoring Requirements

What Is Resmetirom and What Did the FDA Actually Approve?

Resmetirom (brand name Rezdiffra, manufactured by Madrigal Pharmaceuticals) received accelerated approval from the FDA on March 14, 2024, for the treatment of adults with noncirrhotic nonalcoholic steatohepatitis (NASH) and moderate to advanced hepatic fibrosis, defined as stages F2 and F3 [1]. This makes resmetirom the first drug ever approved specifically for NASH (now reclassified as metabolic dysfunction-associated steatohepatitis, or MASH). The approval requires use alongside diet and exercise.

THR-Beta Selectivity and Hepatic Targeting

Resmetirom works as a selective agonist of thyroid hormone receptor beta (THR-beta), which is the dominant thyroid receptor isoform in the liver [2]. By activating THR-beta without significantly engaging THR-alpha (the isoform responsible for cardiac and bone effects), resmetirom reduces hepatic triglyceride content, lowers LDL cholesterol, and decreases markers of liver inflammation. This selectivity is what separates it from systemic thyroid hormones, which carry risks of tachycardia and bone loss.

The Accelerated Approval Distinction

The accelerated approval pathway means the FDA granted approval based on a surrogate endpoint (NASH resolution on biopsy) rather than a confirmed clinical outcome like reduced progression to cirrhosis. Madrigal must complete confirmatory trials demonstrating long-term clinical benefit. If those trials fail, the FDA can withdraw the drug [1]. Clinicians should communicate this distinction to patients.

The MAESTRO-NASH Trial: Primary Evidence for F2-F3

The phase 3 MAESTRO-NASH trial (NCT03900429) enrolled 966 adults with biopsy-confirmed NASH and fibrosis stages F1B through F3 [3]. The trial randomized participants to resmetirom 80 mg, resmetirom 100 mg, or placebo for 52 weeks, with a primary biopsy endpoint at week 52.

NASH Resolution Results

Among patients receiving the 100 mg dose, 25.9% achieved NASH resolution with no worsening of fibrosis at 52 weeks, compared with 9.7% on placebo (P<0.001) [3]. The 80 mg group showed a 22.2% resolution rate. These are modest absolute response rates, but they represent a statistically significant and clinically meaningful separation from placebo in a disease where no pharmacotherapy previously existed.

Fibrosis Improvement Outcomes

For fibrosis improvement of at least one stage without NASH worsening, 25.9% of the 100 mg group met this endpoint versus 14.2% on placebo (P<0.001) [3]. The combined endpoint of both NASH resolution and fibrosis improvement was achieved by approximately 12% of patients on the 100 mg dose. These numbers matter for setting realistic patient expectations.

Lipid and Biomarker Changes

Resmetirom produced meaningful reductions in atherogenic lipids. LDL cholesterol dropped by approximately 14% from baseline on the 100 mg dose, and lipoprotein(a) decreased by roughly 22% [4]. Triglycerides fell by about 18%. These lipid effects are relevant because NASH patients carry a high cardiovascular risk burden, and cardiovascular events remain the leading cause of death in this population [5].

F2-F3 Fibrosis: Why This Staging Window Matters

The fibrosis stage is the single strongest predictor of liver-related mortality in NASH. A 2019 meta-analysis in Hepatology (N=1,495) found that each one-stage increase in fibrosis was associated with a 58% increase in overall mortality and a 240% increase in liver-related mortality [6].

F2 vs. F3: Different Risk Profiles

F2 (significant fibrosis with portal-portal septa) carries a lower 10-year risk of cirrhosis progression than F3 (bridging fibrosis). Patients with F3 fibrosis sit at the threshold of cirrhosis. In MAESTRO-NASH, both F2 and F3 subgroups showed benefit, but the absolute magnitude of benefit was numerically larger in F3 patients [3]. This makes the monitoring window especially important for F3 patients, where disease trajectory decisions carry more weight.

Why F1 and F4 Are Not Included

The FDA label does not cover F0-F1 fibrosis (where the risk-benefit ratio is less clear and natural history is more benign) or F4 cirrhosis (where safety data are insufficient and the underlying hepatic physiology is altered). Prescribing for F4 patients would be genuinely off-label and carries unknown risks related to altered drug metabolism in cirrhotic livers [1].

Monitoring Protocol: What to Track and When

Monitoring resmetirom patients requires a structured schedule. The FDA label specifies thyroid function testing, and clinical practice guidelines from hepatology societies recommend adding liver enzymes, lipid panels, and fibrosis assessments [1] [7].

Baseline Assessment (Before Starting Therapy)

Before initiating resmetirom, clinicians should obtain:

• Thyroid function: TSH and free T4. Resmetirom suppresses TSH in many patients (mean reduction of 30-40% from baseline in MAESTRO-NASH), and baseline values are necessary to interpret changes [3].
• Liver panel: ALT, AST, total bilirubin, alkaline phosphatase, albumin. ALT elevations above 5x the upper limit of normal (ULN) were an exclusion criterion in MAESTRO-NASH.
• Lipid panel: LDL-C, triglycerides, lipoprotein(a) if available.
• Fibrosis staging: FibroScan (vibration-controlled transient elastography) with a controlled attenuation parameter (CAP) score, or serum-based scoring (FIB-4 index, Enhanced Liver Fibrosis [ELF] test). Liver biopsy is the gold standard but is not required for every patient at baseline if non-invasive markers are concordant.
• Body weight and metabolic parameters: BMI, HbA1c, fasting glucose.

Month 3 Assessment

At 12 weeks, repeat:

• TSH and free T4 (to evaluate expected TSH suppression and confirm no clinical hypothyroidism or thyrotoxicosis symptoms)
• ALT and AST (to screen for drug-induced liver injury; transaminase elevations >3x ULN occurred in 3.8% of resmetirom patients vs. 1.9% on placebo in MAESTRO-NASH [3])
• Lipid panel (to confirm expected LDL and triglyceride reduction)

This is also the timepoint for dose escalation from 80 mg to 100 mg daily, per the label [1]. If ALT exceeds 5x ULN, the label advises holding the dose and rechecking within 1-2 weeks.

Month 6 Assessment

Repeat thyroid function, liver enzymes, and lipid panel. By 6 months, TSH should have stabilized. A persistently rising TSH or development of clinical hypothyroidism symptoms should prompt endocrinology consultation. Most TSH suppression in trials was subclinical and did not require intervention [3].

Month 12 and Beyond

At 12 months, the full assessment battery should be repeated, with the addition of:

• Repeat fibrosis assessment: FibroScan or ELF to compare against baseline. If the patient was started based on biopsy, a repeat biopsy may be warranted, particularly in F3 patients, to determine whether bridging fibrosis has improved or progressed.
• Clinical outcome review: Has the patient experienced any signs of liver decompensation (ascites, variceal bleeding, hepatic encephalopathy)? If so, the drug should be stopped and the patient re-staged.

After the first year, monitoring every 6-12 months is reasonable for stable patients. The American Association for the Study of Liver Diseases (AASLD) practice guidance on NAFLD/NASH (updated 2023) recommends ongoing non-invasive fibrosis surveillance in all NASH patients, regardless of treatment [7].

Safety Signals and Adverse Events

Diarrhea was the most common adverse event in MAESTRO-NASH, occurring in 26.7% of the 100 mg group versus 15.1% on placebo [3]. Nausea affected 18.2% of patients. Most gastrointestinal symptoms were mild to moderate and self-limited, peaking in the first 4-8 weeks of treatment.

Thyroid-Related Concerns

TSH suppression occurred in a significant proportion of patients. In the 100 mg group, the mean TSH decrease was approximately 35-40% from baseline [3]. Free T3 levels increased modestly, while free T4 remained relatively stable. No cases of overt hyperthyroidism requiring treatment discontinuation were reported in the key trial, but post-marketing surveillance is ongoing. Patients with pre-existing thyroid disorders (Hashimoto's thyroiditis, Graves' disease in remission) were underrepresented in trials, and monitoring should be more frequent in these groups.

Hepatotoxicity Risk

ALT elevations >3x ULN occurred in 3.8% of patients on the 100 mg dose [3]. Most were asymptomatic and resolved with dose continuation or temporary interruption. No cases of Hy's law (ALT >3x ULN with bilirubin >2x ULN) were confirmed. The prescribing information recommends monthly liver enzyme monitoring for the first 3 months if ALT is elevated at baseline [1].

Drug Interactions

Resmetirom is metabolized primarily by CYP2C8 and CYP3A4 [8]. Strong CYP2C8 inhibitors (gemfibrozil, for example) may increase resmetirom exposure and should be avoided or used with caution. Resmetirom also increases the area under the curve (AUC) of some statins by up to 30%, which is clinically relevant given that most NASH patients are on statin therapy for cardiovascular risk reduction [8]. Monitor for statin-related myopathy and consider dose adjustment.

Dr. Zobair Younossi, Chair of the Global NASH Council, noted in a 2024 commentary: "Resmetirom represents a new treatment approach for MASH, but real-world monitoring will determine whether the histological benefits translate into reduced cirrhosis progression and liver-related mortality" [9].

Practical Prescribing Considerations for F2-F3 Patients

Prescribing resmetirom for confirmed F2-F3 fibrosis falls within the FDA-approved indication. This is not off-label use. The confusion arises because NASH pharmacotherapy is a new category entirely, and many clinicians associate any NASH drug prescription with off-label territory.

Patient Selection

The ideal candidate has biopsy-confirmed or non-invasively confirmed NASH with F2 or F3 fibrosis, no evidence of decompensated liver disease, and adequate thyroid function at baseline. Patients with active hepatitis B or C should have those infections treated first. MAESTRO-NASH excluded patients with alcohol consumption exceeding 21 drinks per week for men or 14 for women [3].

When to Stop Treatment

No consensus guideline defines a stopping rule for resmetirom. Reasonable triggers for discontinuation include:

• Development of decompensated cirrhosis
• ALT persistently >5x ULN despite dose adjustment
• Confirmed progression to F4 on follow-up assessment
• Patient intolerance (persistent GI symptoms refractory to supportive care)
• Completion of confirmatory trial endpoints, if the accelerated approval is withdrawn

Cost and Access

Rezdiffra carries a wholesale acquisition cost of approximately $47,400 per year [10]. Insurance coverage varies widely. Many commercial payers require prior authorization and documentation of fibrosis staging. The manufacturer offers a patient assistance program for eligible uninsured or underinsured patients.

How Resmetirom Compares to Other NASH Approaches

No other FDA-approved pharmacotherapy for NASH existed before resmetirom. Off-label agents that have been used include pioglitazone, vitamin E (800 IU daily for non-diabetic NASH), and GLP-1 receptor agonists such as semaglutide [11].

Pioglitazone

The PIVENS trial (N=247) demonstrated that pioglitazone improved NASH histology in non-diabetic patients, with 47% achieving the primary composite endpoint versus 21% on placebo [12]. Pioglitazone carries risks of weight gain (mean 4.7 kg), fluid retention, and bone fractures. It costs under $30/month generic.

Semaglutide

A phase 2 trial of semaglutide 0.4 mg daily (N=320) showed NASH resolution in 59% of patients versus 17% on placebo, but fibrosis improvement did not reach statistical significance [13]. The ongoing ESSENCE phase 3 trial is evaluating semaglutide 2.4 mg for NASH with F2-F3 fibrosis.

Combination Approaches

Researchers are evaluating resmetirom in combination with GLP-1 receptor agonists. The mechanistic rationale is that resmetirom targets hepatic lipid metabolism via THR-beta activation while GLP-1 agonists address insulin resistance, appetite regulation, and systemic inflammation through distinct pathways. No published combination trial data are available as of May 2026.

Long-Term Outlook and Confirmatory Evidence

Madrigal Pharmaceuticals is required to complete the MAESTRO-NASH 54-month extension and additional confirmatory endpoints demonstrating that histological improvement on biopsy translates to reduced clinical outcomes (progression to cirrhosis, hepatic decompensation events, need for liver transplantation, or liver-related death) [1].

The AASLD 2024 guidance statement acknowledges resmetirom as the first approved NASH therapy and recommends that clinicians "discuss the accelerated approval status, the surrogate nature of the endpoints, and the ongoing confirmatory requirements" with patients before initiating therapy [7].

Dr. Arun Sanyal, principal investigator of MAESTRO-NASH and Professor of Medicine at Virginia Commonwealth University, stated: "The 52-week biopsy data show clear histological benefit, but the field needs the long-term outcomes data to fully define where resmetirom fits in the treatment algorithm for MASH" [14].

Monitoring Summary Table

| Parameter | Baseline | Month 3 | Month 6 | Month 12 | Every 6-12 mo | |-----------|----------|---------|---------|----------|----------------| | TSH, Free T4 | Yes | Yes | Yes | Yes | Yes | | ALT, AST | Yes | Yes | Yes | Yes | Yes | | Total bilirubin, albumin | Yes | No | No | Yes | As needed | | Lipid panel | Yes | Yes | Yes | Yes | Yes | | FibroScan or ELF | Yes | No | No | Yes | Annually | | Body weight, HbA1c | Yes | No | Yes | Yes | Yes | | Liver biopsy | Consider | No | No | Consider (F3) | As indicated |

Patients on concurrent statin therapy should have creatine kinase (CK) checked if they develop new myalgias, given the 30% increase in statin AUC with resmetirom co-administration [8].